Cell Therapy Market Size is slated to increase substantially over 2022-2028, given the strong awareness about the capability of stem cell therapy to enhance collagen production, new healthy skin tissue growth, and hair development. The increasing research and development activities and the potential use of this therapy in replacing damaged heart muscle and improving heart function will further augment industry demand in the years ahead. Cell therapy refers to a technology that replaces dysfunctional or diseased cells with healthy, functioning ones. Bone marrow transplants, whole blood transfusions, and other forms of cell therapy are applicable to treat conditions like neurological diseases and cancer.
High emphasis on end-to-end research and development activities to develop novel therapies is one of the key trends fueling the cell therapy market outlook through 2022-2028. Takeda Pharmaceutical, for instance, launched a 24,000 sq. ft. research and development cell therapy manufacturing facility in Boston, Massachusetts in 2020. Such developments, along with the rising incidence of rheumatoid arthritis among women will amplify the adoption of cell therapy drugs, due to the emergence of stem cell therapy as a new treatment option for patients with autoimmune diseases.
Cell therapy market from the allogenic therapy segment is set to register a high revenue by 2028. This is on account of the ability of the treatment to overcome the limitations of the autologous CAR T-cell paradigm, such as the challenges of leukapheresis, and provide efficacious and accessible CAR therapies. Based on application, the cardiovascular segment will account for an appreciable industry share over the foreseeable future, considering the increased effectiveness of cell-based therapy in treating heart diseases. For example, stem cell therapy can reduce heart attacks and death among patients with chronic heart failure, thus boosting segmental growth over the coming years.
Europe cell therapy market is poised to depict a strong growth rate through 2028, driven by the rapid advancement of the regenerative medicine ecosystem across the region. The increased prevalence of chronic conditions like lung cancer in England will further propel the adoption of cell therapy treatment, as a result of the escalating research activities for CAR-T cell therapy for lung cancer patients. The regional market expansion can further be credited to the growing incidence of neurogenerative conditions like Parkinson’s disease and the mounting healthcare spending in countries like the UK and Germany.
The competitive landscape of the cell therapy industry comprises companies such as Glaxosmithkline, Novartis AG, Pharmicell, Anterogen, BioNTech IMFS, Stemedica Cell Technologies, NuVasive, Kolon TissueGene, Osiris Therapeutics (Smith & Nephew), JCR Pharmaceuticals, Cells for Cells, MEDIPOST, and Vericel Corporation, among others. These companies are focusing on business expansions and new service launches to increase their presence in the global market.
For instance, in December 2021, Kolon TissueGene, Inc. gained U.S. FDA approval to proceed with the Phase II clinical study of TG-C, its novel cell and gene therapy, in patients with hip osteoarthritis (OA). In February 2021, MEDIPOST received approval from the Japanese Ministry of Health, Labour, and Welfare to conduct the Phase 3 clinical trial of its cell therapy, CARTISTEM, in patients diagnosed with mild to moderate knee osteoarthritis.
The Coronavirus disease continues to pose a health burden due to the limited treatment options. Despite showing mild symptoms in most patients, the virus has shown potential to extend beyond the lungs and affect the nervous, cardiovascular, and other organ systems. In order to reduce acute lung injury and cell-mediated complications in patients, various research studies on potential treatment including cell therapies are being conducted. Since cell therapies have regenerative functions, their potential applications in the treatment of COVID-19 may aid overall cell therapy market dynamics over the foreseeable future.
Market, by Therapy
Market, by Application
Market, by End-User
The above information is provided for the following regions and countries: